RVL Pharmaceuticals plc (RVLPQ)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Aug 11, 2025, 2:21 PM EDT
RVL Pharmaceuticals Company Description
RVL Pharmaceuticals plc operates as a specialty pharmaceutical company.
It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary.
It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults.
The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022.
RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
RVL Pharmaceuticals plc
| Country | Ireland |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 125 |
| CEO | Brian Markison |
Contact Details
Address: 400 Crossing Boulevard Bridgewater, 08807 United States | |
| Phone | 908 809 1300 |
| Website | rvlpharma.com |
Stock Details
| Ticker Symbol | RVLPQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | IE00BF2HDL56 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Brian A. Markison | Chairman, President, Chief Executive Officer and Principal Financial Officer |
| James D. Schaub | Executive Vice President and Chief Operating Officer |
| Jarret Miller | Executive Vice President of Human Resources |
| Scott Schroppe | Secretary |